Using PET scans to predict future problems in stroke survivors
Tests whether a whole-body FDG PET scan can predict later problems in stroke patients.
Plain-language title generated from the registry record
Registry title: Cerebral Atherosclerosis Research With Positron Emission Tomography
Key facts
- Where
- Seoul, South KoreaSee the site
Where in South Korea
- Seoul National University HospitalSeoul, South KoreaNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Seoul National University Hospital
- Trial code
- NCT07041372
- Record updated
- 27 June 2025
- Original description
The goal of this clinical trial is to learn if the application of fluorodeoxyglucose positron emission tomography can predict prognosis of stroke patients. The main questions it aims to answer are:Read full original descriptionShow less
Cerebral Atherosclerosis Research With Positron Emission Tomography
The goal of this clinical trial is to learn if the application of fluorodeoxyglucose positron emission tomography can predict prognosis of stroke patients. The main questions it aims to answer are:
* Does FDG PET can predict future vascular events such as stroke recurrence, myocardial infarction or vascular death among stroke survivors? * Does FDG PET can predict other important events such as fracture, dementia, bleeding, cancer and overall death among stroke survivors? Researchers will compare the FDG uptake in major organs - such as the amygdala, vertebrae, spleen, liver, internal carotid artery, visceral fat, and psoas muscle - between patients with and without the event of interest to determine whether FDG PET can predict the overall prognosis of stroke patients.
Participants will:
* Undergo whole-body FDG PET once their neurological status has stabilized after stroke. * Complete questionnaires assessing stress and anxiety (PHQ-9 and PSS-10) on the same day. * Maintain regular clinic visits for up to 24 months following the index stroke
Inclusion: acute ischemic stroke patients who admitted within seven days after symptom onset.
Exclusion: Patients with uncontrolled diabetes requiring persistent insulin injection; Patients with diagnosed/treatment for dementia; Patients undergoing treatment for malignant tumors or serious autoimmune diseases; Patients with unstable vital signs or neurological symptoms; Patients with estimated glomerular filtration rate less than 30ml/min; During pregnancy or while breastfeeding; Patients with impaired consent capacity.